OTC Stock Picks Newsletter Informs Investors of Top Biotech Stock Dynavax Technologies

Stamford, CT (PRWEB) November 09, 2012

OTC Stock Picks is a premier penny stock newsletter focused on bringing investors the next great trading opportunity. The OTC Stock Picks team has been following top biotech Dynavax Technologies for the past several months.

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company which discovers and develops novel products to prevent and treat infectious and inflammatory diseases.

The Company’s lead product candidate is Heplisav, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than currently licensed vaccines.

The U.S. Food and Drug Administration (FDA) has set November 14-15, 2012, to discuss Heplisav’s approvability at the Vaccines and Related Biological Products Advisory Committee panel. The FDA has also established February 24, 2013, as the PDUFA date for Heplisav.

If approved, Heplisav would be the standard-of-care hepatitis B vaccine. It is important to note also, that Dynavax has worldwide commercial rights to Heplisav.

Shares of Dynavax peaked on October 15, 2012 at $ 5.06 per share and have since retreated to the 11/8/12 closing price of $ 4.01. With next weeks scheduled Advisory Committee panel meeting likely to tell the story for potential approval of Heplisav (and analysts predicting an 85% chance of approval), Dynavax shares could start to rally from these levels. Some analysts have a $ 6.00 price target for Dynavax near term.

There is always FDA risk in biotech plays, but OTC Stock Picks believes Dynavax could be a potential short term trade opportunity, or a potential long-term hold with future sales of Heplisav predicted at $ 350MM-$ 500MM.

About OTC Stock Picks

The team is among the US market leaders in connecting penny stocks to investors. With over two decades of market experience, the team prides itself on having the pulse of the penny stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.

Disclaimer: OTC Stock Picks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.

Please visit http://www.otcstockpicks.net for a more complete list of risks and disclosures.

This entry was posted in Biotech and tagged , , , , , , , . Bookmark the permalink.

Leave a Reply